BioArctic flags new press release on Leqembi subcutaneous autoinjector data at AAIC 2026

PUBT · 1d ago
BioArctic flags new press release on Leqembi subcutaneous autoinjector data at AAIC 2026
  • BioArctic posted an AAIC 2026 update on Leqembi’s subcutaneous autoinjector, positioning efficacy and safety as comparable to the IV regimen.
  • Data highlighted PK bioequivalence for weekly 500 mg SC dosing versus 10 mg/kg IV every two weeks, with an exposure ratio of 104%.
  • Release pointed to a potential at-home administration pathway, aiming to broaden access through a fully subcutaneous initiation-to-maintenance option.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202607121130BITN____UKPR__EN_20260712-BIT-8063-0) on July 12, 2026, and is solely responsible for the information contained therein.